Hydroxyprogesterone Caproate Combination Therapy for Tumor Immune Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy for tumors faces challenges due to immune escape mechanisms employed by tumor cells, leading to reduced efficacy, necessitating combination therapies that enhance the effectiveness of immune checkpoint inhibitors.
Innovation Solution
Administering hydroxyprogesterone caproate in conjunction with receptor tyrosine kinase inhibitors and/or anti-PD-1/PD-L1 antibodies to modulate the tumor microenvironment, enhance immune cell infiltration, and improve the efficacy of immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy alone is used to treat tumors, then the treatment approach is simple and specific, but the efficacy is reduced due to immune escape mechanisms
Solution Approach 1:
The patent combines immunotherapy with hydroxyprogesterone caproate and receptor tyrosine kinase inhibitors to create a multi-component treatment regimen. This combination addresses immune escape mechanisms by targeting multiple pathways simultaneously, thereby improving therapeutic efficacy while managing the complexity through coordinated action of different drug classes
Solution Approach 2:
The treatment approach uses a composite therapeutic strategy integrating different mechanisms of action: immune checkpoint inhibitors, hydroxyprogesterone caproate, and receptor tyrosine kinase inhibitors. This composite approach targets both tumor cells and the tumor microenvironment, overcoming resistance mechanisms that would affect single-agent therapy
2Reliability
If combination therapy is used to enhance efficacy, then the anti-tumor effect is improved, but the treatment complexity increases
Solution Approach 1:
The combination therapy is segmented into distinct functional components: immune checkpoint inhibitors for immune activation, hydroxyprogesterone caproate for microenvironment modulation, and receptor tyrosine kinase inhibitors for signaling pathway blockade. This segmentation allows each component to target specific mechanisms while maintaining overall therapeutic coherence
Solution Approach 2:
Hydroxyprogesterone caproate acts as an intermediary agent that modulates the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors. It serves as a bridge between different therapeutic mechanisms, facilitating synergistic effects while managing the complexity of multi-target therapy
Data Source
AI summary
A method for co-administrating hydroxyprogesterone caproate, tyrosine kinase inhibitor, and/or anti-PD-I/PD-LI an-1 tibodies for tumor treatment. The present application also provides a corresponding pharmaceutical use and a pharmaceutical product. Co-administration with hydroxyprogesterone caproate can further improve the therapeutie effect of lenvatinib and anti-PD-I/PD-L1 antibodies against tumors.